Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section
Research
Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
I-Ching Sam*1, Francis Drobniewski*
, Philip More*, Melanie Kemp*, and Timothy Brown*
, Philip More*, Melanie Kemp*, and Timothy Brown*
Table 7
Sequence analysis of 10 discrepant rifampin-susceptibility results*
| Sample no. | Rifampin susceptibility |
||
|---|---|---|---|
| LiPA result | Phenotypic result | Conclusion after sequencing | |
| 1–3 | Sensitive | Resistant | From the same patient; wild-type rpoB test region |
| 4 | Sensitive | Resistant | Mycobacterium bovis; wild-type rpoB test region |
| 5–7 | Resistant (DS4) | Sensitive | From the same patient; synonymous substitution (R528R) not associated with rifampin resistance |
| 8 | Resistant (DS1) | Sensitive | 2 genotypes present: wild-type (predominant) and mutant (L511P) |
| 9 | Resistant (R5) | Sensitive | S531L mutation; wild-type rpoB on retesting, thus likely laboratory error |
| 10 | Resistant (DS2) | Sensitive | D516A mutation; no high-level resistance when seen alone |
*LiPA, line probe assay.
1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia
Page created: January 06, 2012
Page updated: January 06, 2012
Page reviewed: January 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.